Will This Ratings Call Help CyrusOne (CONE) Stock Today?

NEW YORK (TheStreet) -- CyrusOne (CONE) stock has been initiated with a "buy" rating and a $24 price target, UBS said Tuesday. The firm said the company has an attractive external growth profile. 

Must Read: Warren Buffett's 25 Favorite Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

-----------------------

Separately, TheStreet Ratings team rates CYRUSONE INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate CYRUSONE INC (CONE) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • The gross profit margin for CYRUSONE INC is rather low; currently it is at 19.10%. Despite the low profit margin, it has increased significantly from the same period last year. Despite the mixed results of the gross profit margin, CONE's net profit margin of 0.25% is significantly lower than the industry average.
  • In its most recent trading session, CONE has closed at a price level that was not very different from its closing price of one year earlier. This is probably due to its weak earnings growth as well as other mixed factors. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • CYRUSONE INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CYRUSONE INC reported poor results of -$1.32 versus -$0.36 in the prior year. This year, the market expects an improvement in earnings ($0.16 versus -$1.32).
  • Compared to other companies in the Real Estate Investment Trusts (REITs) industry and the overall market, CYRUSONE INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Real Estate Investment Trusts (REITs) industry. The net income increased by 100.9% when compared to the same quarter one year prior, rising from -$21.10 million to $0.20 million.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Tuesday Turnaround: Google Gets Grilled

Tuesday Turnaround: Google Gets Grilled

Nvidia Shares Fall as SoftBank Reportedly Plans to Sell Its Stake

Nvidia Shares Fall as SoftBank Reportedly Plans to Sell Its Stake

Stocks End Mixed as China Trade Progress Offsets D.C. Dysfunction

Stocks End Mixed as China Trade Progress Offsets D.C. Dysfunction

Market Madness: This Market Is for Stock Pickers

Market Madness: This Market Is for Stock Pickers

Jim Cramer: The Operative Term for This Tape Is Treacherous

Jim Cramer: The Operative Term for This Tape Is Treacherous